Announcement:
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma
Get the latest updates from our team on new research, thought leadership, and company news and events.
